[Skip to Content]
[Skip to Content Landing]
March 25, 1998

BRCA1 Testing—Advances and Retreats

Author Affiliations

From the Departments of Laboratory Medicine and Pathology and Oncology, Mayo Clinic and Foundation, Rochester, Minn.

JAMA. 1998;279(12):955-957. doi:10.1001/jama.279.12.955

Since the original localization1 and cloning2 of BRCA1, a key question has been: What proportion of the overall burden of breast cancer is attributable to mutations in this susceptibility gene? Previous studies have focused on 4 categories of individuals: members of high-risk families (those with apparent single-gene, autosomal dominant transmission of susceptibility to breast and/or ovarian cancer); genetically distinctive populations such as persons of Ashkenazi extraction; women with early-onset breast cancer; and women seen in high-risk breast cancer clinics (from moderate- and high-risk families). Findings from select published reports in these groups and highlights of findings of 2 articles in this issue of JAMA are summarized in Table 1.318

First Page Preview View Large
First page PDF preview
First page PDF preview